KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Debt (2016 - 2025)

Alnylam Pharmaceuticals' Total Debt history spans 8 years, with the latest figure at $121.3 million for Q3 2025.

  • For Q3 2025, Total Debt changed N/A year-over-year to $121.3 million; the TTM value through Sep 2025 reached $121.3 million, changed N/A, while the annual FY2024 figure was $93.8 million, N/A changed from the prior year.
  • Total Debt reached $121.3 million in Q3 2025 per ALNY's latest filing, roughly flat from $120.8 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $675.7 million in Q4 2021 to a low of $93.8 million in Q4 2024.
  • Average Total Debt over 3 years is $225.9 million, with a median of $120.8 million recorded in 2025.
  • The largest YoY upside for Total Debt was 253.25% in 2021 against a maximum downside of 253.25% in 2021.
  • A 3-year view of Total Debt shows it stood at $675.7 million in 2021, then tumbled by 86.12% to $93.8 million in 2024, then increased by 29.35% to $121.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Total Debt are $121.3 million (Q3 2025), $120.8 million (Q2 2025), and $118.1 million (Q1 2025).